bluebird bio Appoints O. James Sterling as Chief Financial Officer
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business Wire
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease.“We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets will position us well as we work to prove the commercial gene therapy model, and demonstrate progress on our path to profitability,” said Andrew Obenshain, chief executive officer, bluebird bio.“It is an honor to be joining bluebird bio, a company that has pioneered gene therapy development over the past decade, and today is at the forefront of gene therapy commercialization,” said O. James Sterling. “I look forward to working alongside others in the flock to drive growth, realize value for shar
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- Global Stem Cell Therapy Market Analysis Report 2024-2030, by Therapy Type, Therapeutic Application (Oncology, Cardiovascular Disease, Musculoskeletal Disorders), Region and Segment Forecasts [Yahoo! Finance]Yahoo! Finance
- 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerPR Newswire
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BLUEAccesswire
- bluebird bio, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; May 28, 2024 deadlineGlobeNewswire
- Shareholders of bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUEAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 6/13/24 - Form 3
- 6/4/24 - Form 4
- 5/29/24 - Form 8-K
- BLUE's page on the SEC website